England to Review Rejection of Alzheimer’s Drugs for NHS

England’s drug price regulator will reconsider its decision to rule out using Eli Lilly & Co.’s Alzheimer’s disease treatment — and another made Eisai Co. and Biogen Inc. — in the state-run National Health Service, following successful appeals by the companies....

Redirecting to full article...